ZyVersa Therapeutics, Inc. Warrants
ZVSAW
ZVSAW was delisted on the 20th of December, 2022.
1 hedge funds and large institutions have $0 invested in ZyVersa Therapeutics, Inc. Warrants in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 18 closing their positions.
95% less funds holding
Funds holding: 19 → 1 (-18)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $482K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 18
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EFI
EHP Funds Inc
Toronto,
Canada
|
-$68K |
| 2 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
-$50K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$48K |
| 4 |
Context Capital Management
Lajolla,
California
|
-$45K |
| 5 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
-$33K |
ZVSAW Hedge Fund Activity: Q4 2022 in Review
1 of the 6,241 institutional investors tracked by Wall St. Rank reported a position in ZyVersa Therapeutics, Inc. Warrants (ZVSAW) for Q4 2022, worth a combined $0 — down 100% from $482K a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ZVSAW and 0 opened new positions — a net loss of 18 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was EHP Funds Inc, exiting entirely with an estimated $68K sold.
- 1 institutional investor held ZyVersa Therapeutics, Inc. Warrants (ZVSAW) as of Q4 2022, down from 19 in Q3 2022.
- Funds reported $0 of ZyVersa Therapeutics, Inc. Warrants stock for Q4 2022, down 100% quarter-over-quarter.
- 0 funds opened new ZyVersa Therapeutics, Inc. Warrants positions in Q4 2022 and 18 closed out, a net change of -18 holders.
- The largest ZyVersa Therapeutics, Inc. Warrants seller in Q4 2022 was EHP Funds Inc, an estimated $68K sold.
Based on aggregated 13F filings for Q4 2022.